Paper Details

  1. Home
  2. Paper Details

The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.

Author: BruqueCarlos David, BruzzoneAriana, JabloñskiMartina, LüthyIsabel Alicia, Pérez PiñeroCecilia, RiveroEzequiel Mariano, RodríguezMaría Sol, VanzulliSilvia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Triple-negative breast cancer, a particularly aggressive subtype, lacks specific targeted therapies and is treated with chemotherapy, which can have significant side effects. This study aims to investigate if the dose of chemotherapeutic drugs could be reduced by co-administering it with the β2-agonist salbutamol.
Paper Details　
Original Abstract of the Article :
Globally breast cancer accounts for 24.5% in incidence and 15.5% in cancer deaths in women. The triple-negative subtype lacks any specific therapy and is treated with chemotherapy, resulting in significant side-effects. We aimed to investigate if the dose of chemotherapeutic drugs could be diminishe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00280-023-04586-9

データ提供：米国国立医学図書館（NLM）

Salbutamol: A New Ally in Triple-Negative Breast Cancer Treatment?

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer that lacks targeted therapies. This study investigates the potential synergy between the β2-adrenergic agonist salbutamol and the chemotherapeutic drug paclitaxel in treating TNBC. The researchers found that salbutamol enhances the anti-proliferative effects of paclitaxel, suggesting that combining these drugs may offer a more effective treatment strategy for TNBC. This research is like a desert oasis, offering new and potentially synergistic approaches to combat this aggressive form of cancer.

Combating TNBC: A Synergistic Approach

This study offers a glimmer of hope in the fight against TNBC. The finding that salbutamol enhances the anti-proliferative effects of paclitaxel suggests that combining these drugs could offer a more effective treatment strategy for this aggressive cancer. This research is like a camel caravan, seeking a new and more potent weapon to combat this challenging disease.

A New Frontier in TNBC Treatment: Salbutamol and Paclitaxel

This study opens up new avenues for TNBC treatment. The potential synergy between salbutamol and paclitaxel suggests that these drugs, when combined, could offer a more effective and potentially less toxic treatment option for patients with TNBC. This research is like a desert explorer, uncovering hidden pathways to better treatments for TNBC.

Dr.Camel's Conclusion

This study offers a promising new approach to treating triple-negative breast cancer by exploring the synergistic effects of salbutamol and paclitaxel. The findings suggest that combining these drugs could offer a more effective and potentially less toxic treatment strategy for this aggressive form of cancer. It's like a camel caravan, navigating the challenging desert landscape of cancer treatment, seeking a new and more powerful oasis of hope for patients with TNBC.

Date :
  1. Date Completed 2023-11-13
  2. Date Revised 2023-11-24
Further Info :

Pubmed ID

37725114

DOI: Digital Object Identifier

10.1007/s00280-023-04586-9

Related Literature

Article Analysis
・Side Effects of albuterol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.